9
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The renin–angiotensin system: An integrated view of lung disease and coagulopathy in COVID-19 and therapeutic implications

      article-commentary
      The Journal of Experimental Medicine
      Rockefeller University Press

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Betty Diamond discusses the potential contribution of the renin–angiotensin system to the pathogenies of COVID-19.

          Abstract

          The renin–angiotensin system (RAS) has long been appreciated as a major regulator of blood pressure, but has more recently been recognized as a mechanism for modulating inflammation as well. While there has been concern in COVID-19 patients over the use of drugs that target this system, the RAS has not been explored fully as a druggable target. The abbreviated description of the RAS suggests that its dysregulation may be at the center of COVID-19.

          Related collections

          Author and article information

          Journal
          J Exp Med
          J. Exp. Med
          jem
          The Journal of Experimental Medicine
          Rockefeller University Press
          0022-1007
          1540-9538
          03 August 2020
          18 June 2020
          18 June 2020
          : 217
          : 8
          : e20201000
          Affiliations
          [1]Feinstein Institute Hofstra Medical School/Northwell Health, Manhasset, NY
          Author notes
          Author information
          https://orcid.org/0000-0002-3250-3804
          Article
          jem.20201000
          10.1084/jem.20201000
          7301648
          32556101
          3047f3f2-50aa-4dee-8faa-049fae6850ab
          © 2020 Diamond

          This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

          History
          Page count
          Pages: 3
          Funding
          Funded by: National Institutes of Health, DOI http://dx.doi.org/10.13039/100000002;
          Award ID: NIH P01AI073693
          Award ID: NIH R03-AR065157
          Categories
          Viewpoint
          Infectious Disease and Host Defense

          Medicine
          Medicine

          Comments

          Comment on this article